A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679803 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac550 | DOI Listing |
Publication Analysis
Top Keywords
hepatitis virus
8
pilot trial
4
trial prevention
4
prevention hepatitis
4
virus transmission
4
transmission donor
4
donor organ
4
organ transplant
4
transplant recipient
4
recipient short-course
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!